Researchers at a Roanoke-based biotech company might have discovered a way to extend their therapeutic delivery system’s shelf life. It could lead to big advances in mitigating radiation ...
An epidemiology professor at the University of North Carolina at Chapel Hill (UNC) discussed a population-based study she leads that aims to understand the social and molecular determinants of breast ...
NICE has rejected the use of AstraZeneca and Daiichi Sankyo’s Enhertu as an NHS treatment for advanced HER2-low breast cancer, a decision that the companies have described as “devastating”. The ...
Site: https://ad.doubleclick.net/ddm/trackclk/N46002.1980504THECHARLOTTEPOST0/B33424697.425762596;dc_trk_aid=618889471;dc_trk_cid=238670549;dc_lat=;dc_rdid=;tag_for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback